Robotic microfluidic platform brings AI to lipid nanoparticle design
AI has designed candidate drugs for antibiotic-resistant infections and genetic diseases. But efforts to incorporate AI into the design of lipid nanoparticles (LNPs), the revolutionary delivery vehicles behind mRNA therapies like the COVID-19 vaccines, have been much more limited.
Image: Phys.org
AI has designed candidate drugs for antibiotic-resistant infections and genetic diseases. But efforts to incorporate AI into the design of lipid nanoparticles (LNPs), the revolutionary delivery vehicles behind mRNA therapies like the COVID-19 vaccines, have been much more limited.
Originally published at Phys.org
